S
SonoThera
Ultrasound-mediated nonviral genetic medicines for targeted delivery of therapeutic payloads
About SonoThera
SonoThera is a pioneering startup that is revolutionizing the field of gene therapy. The company is developing an innovative ultrasound-guided nonviral gene therapy platform. This platform is designed to deliver genetic medicines to various human organs using microbubbles, a technique known as sonoporation. This approach is aimed at overcoming the major challenges currently faced in gene therapy, including safety concerns, efficacy, biodistribution, and high costs.
Read full description
SonoThera's primary market is the healthcare sector, specifically in the area of gene therapy. The company's clients are patients who are in need of next-generation genetic medicines. The business model of SonoThera is based on the development and commercialization of its proprietary gene therapy platform. The company generates revenue by providing this platform and the associated therapies to patients.
SonoThera's technology has been successfully used in both preclinical and clinical settings, demonstrating its potential for wide-ranging applications in the field of gene therapy. The team at SonoThera is uniquely qualified to develop these next-generation gene therapies, bringing together expertise in various relevant fields.
In summary, SonoThera is a promising startup with a unique approach to gene therapy. Its ultrasound-guided nonviral gene therapy platform has the potential to overcome the major challenges in the field and provide patients with effective, safe, and cost-effective genetic medicines.
At a glance
- Status
- Operational
- Founded
- 2022
- Headquarters
- South San Francisco, United States
- Employees
- 54
- Open positions
- 3
- Dealroom signal
- 87.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Ultrasound, Non-Invasive medical devices and treatments, Biotech and Pharma, Drug Delivery Systems, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning SonoThera.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jun 2026 | $125M | $500M | Vivo Capital · Alexandria Venture Investments · Illumina Ventures · RA Capital Management | ↗ |
| SERIES AOther financing | Dec 2022 | $61M | $243M | Wilson Sonsini · Johnson & Johnson Innovation · Alexandria Venture Investments · Illumina Ventures | ↗ |
Growth signals
Latest recorded traffic for SonoThera is 6.2K monthly website visits, down 16.2% over the last three months. SonoThera's team grew 10.2% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A22 investors entered at this stage
- WSWilson Sonsini
Johnson & Johnson Innovation
Alexandria Venture Investments
Illumina Ventures
Formic Ventures
ARCH Venture Partners
Eli Lilly
Foothill Ventures
Vertex Ventures HC- LILifespan Investments
Medical Excellence Capital
Vida Ventures
Vivo Capital
RA Capital Management
Otsuka Pharmaceutical
ARK Invest
UCB Ventures
CureDuchenne Ventures
Leaps by Bayer
Duquesne Family Office
SymBiosis
Vertex Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about SonoThera on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See SonoThera’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.